Baron Health Care Fund Reports Strong Q4 2025 Performance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy TMO?
Source: seekingalpha
- Quarterly Growth: For the quarter ending December 31, 2025, the Baron Health Care Fund increased by 13.10%, significantly outperforming the Russell 3000 Health Care Index's 11.92% and the Russell 3000 Index's 2.40%, indicating strong performance in the healthcare sector.
- Key Contributors: Companies such as Eli Lilly, Cidara Therapeutics, and Argenx SE were major contributors this quarter, reflecting ongoing momentum in GLP-1 therapies and innovation in biotechnology, which drove the fund's gains.
- Portfolio Adjustments: The fund added seven new positions and exited ten during the quarter, bringing the total number of positions to 43, demonstrating its agile investment strategy in response to market changes.
- Risk Management Actions: The fund reduced its positions in Stryker and Boston Scientific due to valuation concerns while also decreasing its stake in Arcellx to manage risks associated with increasing competition and regulatory challenges, showcasing its responsiveness to market dynamics.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TMO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TMO
Wall Street analysts forecast TMO stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 501.970
Low
580.00
Averages
658.89
High
750.00
Current: 501.970
Low
580.00
Averages
658.89
High
750.00
About TMO
Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. It also provides purification and filtration technologies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Baron Health Care Fund Reports Strong Q4 2025 Performance
- Quarterly Growth: For the quarter ending December 31, 2025, the Baron Health Care Fund increased by 13.10%, significantly outperforming the Russell 3000 Health Care Index's 11.92% and the Russell 3000 Index's 2.40%, indicating strong performance in the healthcare sector.
- Key Contributors: Companies such as Eli Lilly, Cidara Therapeutics, and Argenx SE were major contributors this quarter, reflecting ongoing momentum in GLP-1 therapies and innovation in biotechnology, which drove the fund's gains.
- Portfolio Adjustments: The fund added seven new positions and exited ten during the quarter, bringing the total number of positions to 43, demonstrating its agile investment strategy in response to market changes.
- Risk Management Actions: The fund reduced its positions in Stryker and Boston Scientific due to valuation concerns while also decreasing its stake in Arcellx to manage risks associated with increasing competition and regulatory challenges, showcasing its responsiveness to market dynamics.
See More
Thermo Fisher CEO Sells 10,000 Shares
- Executive Sell-off: Marc N Casper, Chairman and CEO of Thermo Fisher, sold 10,000 shares on March 3, 2026, which may raise market concerns about the company's future performance, as executive sell-offs are often viewed as negative signals regarding company outlook.
- Market Reaction: Such sell-off actions could lead to a decline in investor confidence in Thermo Fisher, potentially impacting its stock performance, especially in the current market environment where investors are particularly sensitive to executive signals.
- Shareholding Structure Change: This transaction may alter Casper's ownership percentage, further influencing market perceptions of management stability, particularly as the company faces increasing competition.
- Strategic Implications: While the sell-off may be interpreted as a negative signal, it could also be part of the executive's personal financial planning, prompting investors to focus on the company's future performance and strategic direction to assess its long-term investment value.
See More
Kemnay Advisory Services Increases Stake in MercadoLibre
- Share Acquisition Details: Kemnay Advisory Services Inc. increased its position in MercadoLibre by 1,385 shares during Q4 2026, with an estimated trade value of $2.91 million, bringing total holdings to 5,623 shares and reflecting a $1.42 million increase from the previous quarter due to both trading and stock price effects.
- Holding Proportion Analysis: Following this purchase, Kemnay's stake in MercadoLibre represents 1.71% of its 13F AUM, indicating a sustained bullish outlook on the company despite a 3.77% decline in share price over the past year.
- Market Performance Overview: As of February 16, 2026, MercadoLibre shares were priced at $1,988.26, with a market capitalization of $100.80 billion, maintaining rapid revenue growth despite pressures from increased e-commerce competition and rising bad loans.
- Investor Outlook: Kemnay has held MercadoLibre shares since Q2 2020, having previously sold off shares, but has now added shares in each of the last four quarters, suggesting they view the current stock price as an attractive buying opportunity, potentially leading to further purchases in the future.
See More
Kemnay Increases MercadoLibre Holdings by 1,385 Shares
- Share Increase: Kemnay Advisory Services Inc. disclosed a purchase of 1,385 shares of MercadoLibre in Q4 2026, with an estimated trade value of $2.91 million, indicating confidence in the company's prospects.
- Holding Status: As of February 2026, Kemnay's total holdings in MercadoLibre reached 5,623 shares, reflecting a $1.42 million increase from the previous quarter, showcasing a positive market sentiment.
- Market Performance: Despite MercadoLibre's share price declining by 3.77% over the past year and trailing the S&P 500 by 15.56 percentage points, Kemnay's increased stake suggests they view the current price as attractive.
- Investment Opportunity: Since acquiring shares in Q2 2020, Kemnay's recent purchases over the last four quarters may indicate confidence in the company's growth potential, particularly as economic conditions improve in Argentina and Venezuela.
See More
Novo Nordisk Invests €432 Million to Expand Wegovy Production
- Investment Expansion: Novo Nordisk announced a €432 million ($506 million) investment in Ireland to expand production capacity for the Wegovy pill, aiming to meet future global demand, particularly outside the U.S. market.
- Competitive Pressure: This investment follows Novo losing market share to Eli Lilly, with analysts noting that despite competitive pressures, this move demonstrates the company's commitment to the oral medication market, potentially helping to restore market confidence.
- Supply Assurance: Novo has stated that it has resolved supply issues for Wegovy and has enough product to meet U.S. demand; however, challenges remain in meeting global demand, especially as it seeks to launch in other countries.
- Future Outlook: The construction projects in Ireland are set to be completed gradually between 2027 and 2028, expected to include technological upgrades of existing facilities, further enhancing Novo's competitiveness in the obesity drug market, particularly in its strategic focus on oral medications.
See More
AIM Immunotech Inc. Enters Agreement with Thermo Fisher for Phase 3 Trial of Ampligen
Agreement Announcement: AIM Immunotech has signed an agreement with the Thermo Fisher Scientific for the Phase 3 trial of its drug Ampligen.
Trial Focus: The Phase 3 trial will focus on evaluating the efficacy and safety of Ampligen in treating specific medical conditions.
See More
Baron Health Care Fund Reports Strong Q4 2025 Performance
- Quarterly Growth: For the quarter ending December 31, 2025, the Baron Health Care Fund increased by 13.10%, significantly outperforming the Russell 3000 Health Care Index's 11.92% and the Russell 3000 Index's 2.40%, indicating strong performance in the healthcare sector.
- Key Contributors: Companies such as Eli Lilly, Cidara Therapeutics, and Argenx SE were major contributors this quarter, reflecting ongoing momentum in GLP-1 therapies and innovation in biotechnology, which drove the fund's gains.
- Portfolio Adjustments: The fund added seven new positions and exited ten during the quarter, bringing the total number of positions to 43, demonstrating its agile investment strategy in response to market changes.
- Risk Management Actions: The fund reduced its positions in Stryker and Boston Scientific due to valuation concerns while also decreasing its stake in Arcellx to manage risks associated with increasing competition and regulatory challenges, showcasing its responsiveness to market dynamics.
See More
Thermo Fisher CEO Sells 10,000 Shares
- Executive Sell-off: Marc N Casper, Chairman and CEO of Thermo Fisher, sold 10,000 shares on March 3, 2026, which may raise market concerns about the company's future performance, as executive sell-offs are often viewed as negative signals regarding company outlook.
- Market Reaction: Such sell-off actions could lead to a decline in investor confidence in Thermo Fisher, potentially impacting its stock performance, especially in the current market environment where investors are particularly sensitive to executive signals.
- Shareholding Structure Change: This transaction may alter Casper's ownership percentage, further influencing market perceptions of management stability, particularly as the company faces increasing competition.
- Strategic Implications: While the sell-off may be interpreted as a negative signal, it could also be part of the executive's personal financial planning, prompting investors to focus on the company's future performance and strategic direction to assess its long-term investment value.
See More
Kemnay Advisory Services Increases Stake in MercadoLibre
- Share Acquisition Details: Kemnay Advisory Services Inc. increased its position in MercadoLibre by 1,385 shares during Q4 2026, with an estimated trade value of $2.91 million, bringing total holdings to 5,623 shares and reflecting a $1.42 million increase from the previous quarter due to both trading and stock price effects.
- Holding Proportion Analysis: Following this purchase, Kemnay's stake in MercadoLibre represents 1.71% of its 13F AUM, indicating a sustained bullish outlook on the company despite a 3.77% decline in share price over the past year.
- Market Performance Overview: As of February 16, 2026, MercadoLibre shares were priced at $1,988.26, with a market capitalization of $100.80 billion, maintaining rapid revenue growth despite pressures from increased e-commerce competition and rising bad loans.
- Investor Outlook: Kemnay has held MercadoLibre shares since Q2 2020, having previously sold off shares, but has now added shares in each of the last four quarters, suggesting they view the current stock price as an attractive buying opportunity, potentially leading to further purchases in the future.
See More
Kemnay Increases MercadoLibre Holdings by 1,385 Shares
- Share Increase: Kemnay Advisory Services Inc. disclosed a purchase of 1,385 shares of MercadoLibre in Q4 2026, with an estimated trade value of $2.91 million, indicating confidence in the company's prospects.
- Holding Status: As of February 2026, Kemnay's total holdings in MercadoLibre reached 5,623 shares, reflecting a $1.42 million increase from the previous quarter, showcasing a positive market sentiment.
- Market Performance: Despite MercadoLibre's share price declining by 3.77% over the past year and trailing the S&P 500 by 15.56 percentage points, Kemnay's increased stake suggests they view the current price as attractive.
- Investment Opportunity: Since acquiring shares in Q2 2020, Kemnay's recent purchases over the last four quarters may indicate confidence in the company's growth potential, particularly as economic conditions improve in Argentina and Venezuela.
See More
Novo Nordisk Invests €432 Million to Expand Wegovy Production
- Investment Expansion: Novo Nordisk announced a €432 million ($506 million) investment in Ireland to expand production capacity for the Wegovy pill, aiming to meet future global demand, particularly outside the U.S. market.
- Competitive Pressure: This investment follows Novo losing market share to Eli Lilly, with analysts noting that despite competitive pressures, this move demonstrates the company's commitment to the oral medication market, potentially helping to restore market confidence.
- Supply Assurance: Novo has stated that it has resolved supply issues for Wegovy and has enough product to meet U.S. demand; however, challenges remain in meeting global demand, especially as it seeks to launch in other countries.
- Future Outlook: The construction projects in Ireland are set to be completed gradually between 2027 and 2028, expected to include technological upgrades of existing facilities, further enhancing Novo's competitiveness in the obesity drug market, particularly in its strategic focus on oral medications.
See More
AIM Immunotech Inc. Enters Agreement with Thermo Fisher for Phase 3 Trial of Ampligen
Agreement Announcement: AIM Immunotech has signed an agreement with the Thermo Fisher Scientific for the Phase 3 trial of its drug Ampligen.
Trial Focus: The Phase 3 trial will focus on evaluating the efficacy and safety of Ampligen in treating specific medical conditions.
See More
